DPX-Survivac Elicits Anti-Cancer Immune Activity in Recurrent OC, Data Show

DPX-Survivac Elicits Anti-Cancer Immune Activity in Recurrent OC, Data Show
DPX-Survivac combined with intermittent low-dose cyclophosphamide can generate significant anti-tumor immune responses that correlate with tumor regression in women with recurrent advanced ovarian cancer, latest results from the DECIDE1 Phase 2 trial show. Interim data announced by DPX-Survivac's developer, IMV, revealed that all 15 patients with smaller tumors (less than 5 cm at the study's start) experienced some level of clinical benefit from the combo treatment. This confirms prior Phase 1 findings demonstrating that smaller tumors had better responses to the combined treatment. Among these patients, four had their tumors regress enough to be considered a partial response, and remained without signs of disease progression over a significant period of time, researchers said. DECIDE1's most recent results are being presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31-June 4 in Chicago, in a poster titled “DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE1 trial): T cell responses and tumor infiltration correlate with tumor regression." DPX-Survivac is an investigational immunotherapy designed to activate T-cells and boost their ability to recognize and attack cancer cells, specifically those that have at their surface a protein called survivin. Survivin is a protein that is overproduced in more than 20 solid and blood cancers. It plays an important role in tumor progression, supporting its survival and growth. It is also associated with more aggressive cancers and their resistance to chemotherapy. Thus, the protein is seen as a promising tumor-associated antigen, with the potential to
Subscribe or to access all post and page content.